Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28384327 | 0.85 | SLC16A3 (0.39) | SLC16A3ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL19410197 | 0.83 | SLC16A3 (0.46) | SLC16A3ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL19410132 | 0.81 | RECQL (0.40) | SLC16A3ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL19410169 | 0.79 | SLC16A3 (0.36) | SLC16A3ALDH1A1AKR1B1HTR2CSLC6A4 | |
| SCHEMBL19410199 | 0.78 | PLK1 (0.46) | ALDH1A1RECQLHDAC10HDAC6MAPT | |
| SCHEMBL30711153 | 0.78 | SLC16A3 (0.49) | SLC16A3ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL19410138 | 0.72 | SLC16A3 (0.46) | SLC16A3ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL19410139 | 0.72 | SLC16A3 (0.46) | SLC16A3ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL30711162 | 0.72 | SLC16A3 (0.46) | SLC16A3ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL19410182 | 0.72 | ALDH1A1 (0.46) | ALDH1A1KDM4EKMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440097-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-110997698-B | Immunomodulatory agents acting as PD-1 antagonists | 百时美施贵宝公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11066445-B2 | Immunomodulators acting as antagonists of PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066445-B2 | Immunomodulators acting as antagonists of PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200172578-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200172578-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-04 | — | — | US | disclosed |
| EP-3642220-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | Bristol-Myers Squibb Company (US) | 2020-04-29 | — | — | EP | disclosed |
| CN-110997698-A | Immunomodulators acting as PD-1 antagonists | 百时美施贵宝公司 | 2020-04-10 | — | — | CN | disclosed |
| US-10358463-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-23 | — | — | US | disclosed |
| US-10358463-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-23 | — | — | US | disclosed |
| EP-3440097-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2018237153-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-27 | — | — | WO | disclosed |
| WO-2017176608-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176608-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283463-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | SLC16A3 3875/4885ALDH1A1 3723/4885KDM4E 2736/4885 |
| US-10358463-B2 | Immunomodulators | CD274, PDCD1, PDCD1LG2 | SLC16A3 3875/4885ALDH1A1 3723/4885KDM4E 2736/4885 |
| US-20200172578-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | CD274, PDCD1, PDCD1LG2 | SLC16A3 3333/4885ALDH1A1 4359/4885KDM4E 3194/4885 |
| US-11066445-B2 | Immunomodulators acting as antagonists of PD-1 | CD274, PDCD1, PDCD1LG2 | SLC16A3 3386/4885ALDH1A1 3710/4885KDM4E 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.